Clinical trials: Inflammatory Bowel Disease 1
Crohn Disease (CD), Ulcerative Colitis (UC)
the REMONO-CD and the REMONO-UC Studies
Infliximab was the first-in-class anti-TNF agent approved for treating patients with IBD, both for Crohn's disease (CD)1 and ulcerative colitis (UC)2.
- Trial name
- REMONO (NCT07564609)
- Where
- 18 sites in France
- Volunteers
- 420 people
- Sponsor
- University Hospital, Clermont-Ferrand
Ulcerative Colitis (UC), IBD (Inflammatory Bowel Disease)
The Prospective Improved Vitamin D Study for Inflammatory Bowel Disease Patients
The aim of this clinical trial is to gain a better understanding of the effect of Vitamin D supplementation on disease activity and overall health. The main questions it aims to answer are: 1.
- Conditions
- Ulcerative Colitis (UC), IBD (Inflammatory Bowel Disease), Crohn Disease (CD)
- Trial name
- PIVD (NCT07177157)
- Testing
- Vitamin D3 (Cholecalciferol)
- Where
- Canada
- Volunteers
- 150 people
- Sponsor
- Terry Ponich
Crohn Disease
The Innate Immune Response and Enteric Nervous System in Crohn's Disease.
The study aims to explore the relationships between inflammation, nerve changes, and the expression of interferon-stimulated proteins in inflamed and non-inflamed bowel areas from patients with Crohn's disease.
- Trial name
- NCT06485193
- Testing
- Immunohistochemistry
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- Aalborg University Hospital
Inflammatory Bowel Diseases, Crohn Disease
Patient Automated Text Hovering for IBD
This is a 2-arm randomized trial aimed at leveraging behavioral science principles to improve patient engagement between office visits among patients with inflammatory bowel disease (IBD).
- Conditions
- Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
- Trial name
- PATH-IBD (NCT04388865)
- Testing
- Control, Text-based Clinical Hovering
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of Pennsylvania
Crohn's Disease
Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab
To assess the clinical efficacy of subcutaneous (sc) certolizumab pegol administration over 26 weeks in patients suffering from Crohn's Disease (CD) and previously treated with infliximab
- Trial name
- NCT00308581
- Testing
- Certolizumab pegol
- Where
- 107 sites in United States, Austria and 12 more
- Volunteers
- 539 people
- Sponsor
- UCB Pharma
Ulcerative Colitis
Efficacy of Golimumab in Maintaining Deep Remission in UC Patients in Prolonged Remission With Infliximab
This study monitors the efficacy and safety of Golimumab in maintaining deep remission and quality of life in Ulcerative Colitis patients in deep prolonged remission with Infliximab.
- Trial name
- Switch (NCT02868398)
- Where
- Greece
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Evangelismos Hospital
Crohn's Disease in Remission
A Pilot Study Examining Low Sulfur Diet as Treatment for Persistent Symptoms in Quiescent Crohn's Disease
The goal of this study is to learn about a low sulfur diet in patients with Crohn's disease. Study participants will be randomized to receive a low sulfur diet or usual diet for 8 weeks.
- Trial name
- NCT05849012
- Testing
- Low Sulfur Diet, Usual Diet
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Michigan
Crohn's Disease
Beta Carotene From Natural Source for Patients With Non-Active Crohn's Disease
Many inflammatory disorders in the body are linked to oxidative tissue damage. Anti-oxidants that are present in many natural food sources may provide protection from such damage.
- Trial name
- NCT00275418
- Testing
- beta carotene from Dunaliella algae
- Where
- Israel
- Volunteers
- 300 people
- Sponsor
- Bnai Zion Medical Center
Crohn's Disease
Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease
ISIS 2302 is an antisense oligonucleotide drug that reduces the production of a specific protein called intercellular adhesion molecule (ICAM-1), a substance that plays a significant role in the increase of inflammation.
- Trial name
- NCT00048113
- Testing
- Alicaforsen
- Where
- 30 sites in United States, Canada
- Volunteers
- 150 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Crohn Disease
An Australian Study of Mesenchymal Stromal Cells for Crohn's Disease
Despite the advent of newer biologic therapies such as infliximab for Crohn's disease, a form of autoimmune inflammatory bowel disease, a proportion of patients are refractory to such therapy and require surgery.
- Trial name
- NCT01090817
- Testing
- Mesenchymal stromal cells (MSC) for infusion
- Where
- Australia
- Volunteers
- 21 people
- Sponsor
- R.P.Herrmann
Crohn's Disease
Efficacy and Safety of Two Treatment Algorithms in Adults With Moderate to Severe Crohn's Disease
The primary objective of this study was to demonstrate that tight control of disease activity, using stringent criteria based on Crohn's disease activity Index (CDAI), biomarkers (high sensitivity C-reactive protein [hs-CRP] and…
- Trial name
- CALM (NCT01235689)
- Testing
- Adalimumab, Prednisone, Azathioprine
- Volunteers
- 252 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Crohn's Disease
Semapimod for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment Versus Placebo
Assessment of the number of days' treatment with semapimod necessary for efficacy, as measured by response rate to CNI-1493 as compared to placebo, in patients with moderate to severe Crohn's disease (CD).
- Trial name
- CD04 (NCT00739986)
- Testing
- Semapimod
- Where
- 28 sites in United States, Belgium and 3 more
- Volunteers
- 152 people
- Sponsor
- Ferring Pharmaceuticals
Crohn Disease (CD)
Health Benefits of Tart Cherry in Crohn's Disease
Crohn's disease (CD) is a long-term inflammatory condition of the digestive tract. People with CD often experience unpredictable and debilitating symptoms, including abdominal pain, diarrhea, and fatigue.
- Trial name
- NCT06901986
- Testing
- Montmorency tart cherry
- Volunteers
- 52 people
- Sponsor
- University of Central Lancashire
Rectovaginal Fistula, Crohn Disease
Treatment of Rectovaginal Crohn's Fistula by Combination of TAAM Injection and Biological Plug Placement
Interventional, prospective, randomized, controlled, double blind, parallel groups, nonprofit, single center trial
- Trial name
- LIPOPLUG (NCT06813768)
- Testing
- Microfractured adipose tissue injection and plug placement
- Where
- Italy
- Volunteers
- 3 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Intestinal Disease, Inflammatory Bowel Diseases
Validation of CapsoVision CapsoCam® SV-3 Capsule Endoscopy System
To validate an updated version of CapsoCam® SV-3 Endoscopy System brand name CapsoCam Plus™) with respect to the reproducibility of the system to capture and download small bowel images in a manner consistent with the predicate…
- Conditions
- Intestinal Disease, Inflammatory Bowel Diseases, Crohn Disease, Ulcer
- Trial name
- NCT04573959
- Testing
- SV-3 Capsule Endoscopy
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Capso Vision, Inc.
Crohn Disease
Biologics and Partial Enteral Nutrition Study
Crohn's disease (CD) is a chronic, incurable condition associated with inflammation in the gut lining. It causes diarrhoea, severe abdominal pain, poor nutrition and adversely affects the quality of life of sufferers.
- Trial name
- BIOPIC (NCT04859088)
- Testing
- Partial Enteral Nutrition
- Where
- 4 sites in United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- NHS Greater Glasgow and Clyde
Crohn's Disease, Ulcerative Colitis
The Influence of Information Sources on Knowledge and Anxiety in Inflammatory Bowel Disease Patients
Inflammatory Bowel Diseases (IBD) are life-long, incurable illnesses that can have a profound effect on the patients quality of life.
- Conditions
- Crohn's Disease, Ulcerative Colitis, Anxiety
- Trial name
- NCT01916161
- Testing
- Questionnaire
- Where
- United Kingdom
- Volunteers
- 307 people
- Sponsor
- National Health Service, United Kingdom
Inflammatory Bowel Disease (IBD), Crohn Disease (CD)
Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)
The SHIFT-IBD Study is being conducted at multiple medical centers across Canada to evaluate how well guselkumab (Tremfya) works for people with inflammatory bowel disease (IBD) who haven't responded well enough to ustekinumab.
- Conditions
- Inflammatory Bowel Disease (IBD), Crohn Disease (CD), Ulcerative Colitis (UC), IBD-unclassified (IBD-U)
- Trial name
- SHIFT-IBD (NCT07245394)
- Testing
- Guselkumab (Tremfya)
- Where
- 14 sites in Canada
- Volunteers
- 200 people
- Sponsor
- TIDHI Innovation Inc.
Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Crohn's Disease (CD)
Research on the Whole Process of AI Intelligent Management System for the Diagnosis and Treatment of Inflammatory Bowel Diseases
Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is a chronic immune-mediated disorder requiring long-term management.
- Conditions
- Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Crohn's Disease (CD), Ulcerative Colitis (UC), Artificial Intelligence (AI)
- Trial name
- NCT07590271
- Where
- Taiwan
- Volunteers
- 4,500 people
- Sponsor
- Taichung Veterans General Hospital
Ulcerative Colitis, Crohn Disease
Microbial and Human Determinants of the Onset of IBD Flares
This is a longitudinal, observational study that aims to identify the microbial and human molecular triggers of IBD flares via stool, saliva, and blood metatranscriptomes, whole blood proteome, and collected clinical metadata.
- Conditions
- Ulcerative Colitis, Crohn Disease, Irritable Bowel, Crohns Disease Aggravated
- Trial name
- NCT05463900
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Viome
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.